PPHN nursing: persistent pulmonary hypertension of the newborn

Persistent pulmonary hypertension of the newborn (PPHN) is a circulatory crisis in which the pulmonary vascular resistance (PVR) fails to fall after birth. In normal transition, the first breath and the rise in arterial oxygen tension trigger a rapid drop in PVR, redirecting blood from the placenta through the lungs. In PPHN, this transition does not happen — PVR stays at or near fetal levels, pulmonary artery pressure remains elevated, and deoxygenated blood bypasses the lungs entirely through fetal shunts that should have closed. The result is severe, often refractory hypoxemia in an infant who has lungs that may be structurally intact.

PPHN affects roughly 2 per 1,000 live births and carries a mortality rate of 10–20% even with modern therapy. It occurs predominantly in term and near-term infants (≥34 weeks), which makes it clinically distinct from most other neonatal respiratory conditions that concentrate in the preterm population. For nurses working in the NICU or level II/III nurseries, PPHN demands precise hemodynamic monitoring, strict adherence to minimal stimulation protocols, and the clinical judgment to recognize a deteriorating trend before it becomes a cardiac arrest.

This reference covers the pathophysiology, causes, bedside diagnosis, treatment ladder from supplemental oxygen through extracorporeal membrane oxygenation (ECMO), nursing priorities, and long-term outcomes. For the broader neonatal assessment framework, see the neonatal nursing reference. For the delivery room management that precedes PPHN, see neonatal resuscitation nursing.

Pathophysiology: the failed vascular transition

Understanding PPHN requires understanding what normally happens at birth.

Fetal circulation is designed to bypass the lungs, which perform no gas exchange in utero. PVR is high (maintained by hypoxia, acidosis, and circulating vasoconstrictors), and pulmonary blood flow accounts for only 8–10% of combined ventricular output. Almost all blood is shunted away from the lungs through two fetal channels: the foramen ovale (connecting the right atrium to the left atrium) and the ductus arteriosus (connecting the pulmonary artery to the aorta). The placenta — not the lungs — oxygenates the blood.

At birth, three events converge to drive PVR down and pulmonary blood flow up:

1. The lungs inflate with air for the first time, mechanically stretching pulmonary vessels and reducing their resistance.
2. Alveolar oxygen tension rises, which is a potent direct vasodilator of pulmonary vasculature.
3. Bradykinin and prostacyclin levels rise, further dilating pulmonary vessels while nitric oxide production from vascular endothelium surges.

Simultaneously, systemic vascular resistance (SVR) rises sharply with cord clamping. This pressure reversal closes the foramen ovale (functional closure within minutes, anatomical closure over weeks) and reverses flow through the ductus arteriosus, which then constricts and closes over 12–72 hours in response to rising oxygen tension and falling prostaglandin E2.

In PPHN, this transition fails. PVR remains elevated — equal to or exceeding SVR — so right-to-left shunting through the foramen ovale and ductus arteriosus continues at a fetal level. Deoxygenated blood from the right side of the heart enters systemic circulation without passing through the pulmonary capillary bed. The result is hypoxemia that may be profound and is characteristically unresponsive to supplemental oxygen — because the oxygen cannot reach the shunted blood.

The right ventricle, which is designed for a low-pressure pulmonary circuit, must now pump against high resistance. Right ventricular hypertension causes the interventricular septum to bow leftward (D-sign on echocardiogram), impairing left ventricular filling and potentially causing left heart failure on top of the primary problem.

Causes and risk factors

PPHN is not a single disease — it is a final common pathway for several distinct mechanisms that share the outcome of failed PVR reduction. The underlying cause shapes both prognosis and treatment response.

Who gets PPHN? Term and near-term infants (≥34 weeks) account for the vast majority of cases. Smaller premature infants can develop pulmonary hypertension, but the mechanism is more often related to BPD-associated vascular remodeling and is a distinct clinical entity. Male sex, cesarean delivery without labor, and maternal diabetes are associated risk factors. Maternal SSRIs — particularly late in the third trimester — have been linked to PPHN in some cohort studies, though the absolute risk elevation is small.

Clinical presentation

The hallmark of PPHN is cyanosis disproportionate to the degree of respiratory distress — or cyanosis unresponsive to supplemental oxygen that cannot be explained by primary lung disease alone. Respiratory rate is typically elevated (>60/min), and work of breathing may be increased, but the degree of respiratory distress is often less extreme than the degree of hypoxemia would predict. This is the bedside clue: an infant who looks “not that distressed” but has an SpO2 in the 60s or 70s on high-flow oxygen should trigger immediate consideration of PPHN.

Associated findings include:

• Tachycardia (right ventricular strain response)
• Single S2 or loud P2 on auscultation (elevated pulmonary artery pressure transmitted through the pulmonary valve closure)
• Harsh systolic murmur (tricuspid regurgitation from right ventricular dilatation)
• Hypotension (low cardiac output from right ventricular failure and impaired left ventricular filling)
• Metabolic acidosis (lactic acidosis from systemic hypoperfusion)

The defining bedside finding is the pre/post-ductal oxygen saturation gradient, which is explained in the next section.

Diagnosis

Pre/post-ductal SpO2 gradient

The anatomical basis of this test is the location of the ductus arteriosus. The ductus connects the main pulmonary artery to the descending aorta, distal to the origin of the right subclavian artery. The right hand is therefore perfused by pre-ductal blood (oxygenated blood from the left heart, before the shunt point) while the feet are perfused by post-ductal blood (a mixture of oxygenated and shunted deoxygenated blood).

Note: A significant pre/post-ductal gradient confirms ductal-level shunting, but some PPHN patients shunt primarily at the foramen ovale — in those cases both hands and feet may show equally low saturations with no gradient. Absence of a gradient does not exclude PPHN.

Hyperoxia test

The hyperoxia test — placing the infant in 100% oxygen for 10–15 minutes and measuring PaO2 via arterial blood gas — was historically used to distinguish PPHN from cyanotic congenital heart disease (CHD). In PPHN, PaO2 typically rises above 100 mmHg with 100% FiO2 (because the lung parenchyma is capable of oxygenation — it is simply being bypassed). In fixed cyanotic CHD, PaO2 remains below 100 mmHg regardless of FiO2 because the anatomical shunt cannot be overcome by raising alveolar oxygen.

Limitations: the hyperoxia test has declining clinical utility. Many PPHN patients (especially severe MAS or CDH) will not respond, and the test risks hyperoxia-mediated oxidative injury. Echocardiography has largely replaced it as the diagnostic standard.

Echocardiography

Echocardiography (ECHO) is the definitive diagnostic tool for PPHN. Key findings include:

• Elevated pulmonary artery pressure (estimated from tricuspid regurgitation jet velocity via Bernoulli equation; systolic PAP ≥50% of systemic BP is diagnostic)
• Right-to-left or bidirectional shunting across the foramen ovale and/or ductus arteriosus on color Doppler
• Flattening or leftward bowing of the interventricular septum (D-sign) indicating right ventricular pressure overload
• Right ventricular hypertrophy and dilatation
• Normal cardiac anatomy — ruling out structural CHD as the cause of cyanosis

Oxygenation Index (OI)

The Oxygenation Index quantifies severity and guides escalation decisions. It integrates the FiO2 required, the mean airway pressure (MAP) being applied, and the resulting PaO2:

OI = (FiO2 × MAP × 100) / PaO2

Where FiO2 is expressed as a decimal (0.40–1.00), MAP is in cmH2O, and PaO2 is from an arterial blood gas in mmHg (pre-ductal preferred).

A rising OI trend is more clinically meaningful than a single value. An infant whose OI is climbing from 20 to 28 over four hours needs escalation before reaching 40.

Treatment

PPHN treatment follows a stepwise escalation ladder. Each step should be optimized before adding the next intervention, but clinical deterioration may require rapid simultaneous escalation.

Inhaled nitric oxide: mechanism and weaning

iNO is the first-line pulmonary vasodilator for PPHN. It works by diffusing from the alveolus directly into adjacent pulmonary vascular smooth muscle cells, where it activates guanylate cyclase → increases cyclic GMP (cGMP) → smooth muscle relaxation → vasodilation. Because iNO is rapidly inactivated by hemoglobin in the bloodstream, its effect is confined to ventilated lung regions — it does not cause systemic hypotension, which makes it pharmacologically elegant and clinically safe at therapeutic doses.

Standard starting dose is 20 ppm. Doses above 20 ppm do not improve efficacy but increase methemoglobinemia risk. A response is defined as an increase in pre-ductal SpO2 of ≥10–20% or an OI reduction within 30–60 minutes.

iNO weaning protocol: Abrupt discontinuation of iNO triggers rebound pulmonary hypertension — a sudden worsening of PVR that can be more severe than the original presentation. This occurs because exogenous NO downregulates endogenous NO synthase during therapy. Weaning must be gradual:

1. Begin weaning when OI falls below 10–15 and FiO2 ≤ 0.50 for ≥4–6 hours
2. Reduce iNO by 5 ppm increments (e.g., 20 → 15 → 10 → 5 → 1 ppm → off)
3. Wait at least 30–60 minutes at each step; monitor SpO2 and OI continuously
4. If pre-ductal SpO2 drops > 5% or OI rises significantly, return to the previous dose for 4 hours before retrying
5. Sildenafil is often used as a bridge during the final weaning steps to prevent rebound

A key NCLEX fact: never wean iNO abruptly. This is the most frequently tested point about iNO management.

Nursing priorities

Minimal stimulation protocol

This is the cornerstone of PPHN nursing care. Pulmonary vascular resistance in PPHN is exquisitely sensitive to agitation, pain, and stimulation. Any noxious stimulus — suctioning, painful procedures, even assessment manipulations — can trigger reflex pulmonary vasoconstriction, spike the PVR, worsen right-to-left shunting, and drop saturations precipitously. These desaturations can be difficult to recover from and may contribute to hypoxic brain injury.

Cluster care: Group all nursing interventions (assessment, line care, repositioning, mouth care) into a single brief interaction window. Allow the infant to rest undisturbed between these windows. Document the number and duration of stimulation events per shift.

Avoid routine suctioning: Endotracheal suctioning is one of the most potent stimulation events in the NICU. Suction only when clinically indicated (audible secretions, visible secretions, rising airway pressures, acute deterioration consistent with obstruction) — never on a routine time-based schedule.

Pre-medicate before procedures: For any necessary procedure beyond gentle assessment, administer ordered analgesia/sedation before stimulating the infant.

Pain and sedation management

Morphine (0.05–0.1 mg/kg IV) is the standard analgesic in PPHN — it both relieves pain and has mild pulmonary vasodilatory properties. Midazolam (0.05–0.1 mg/kg IV) is used for sedation when additional anxiolysis is needed, particularly during procedures. Continuous low-dose infusions are often used in the most critically ill patients to maintain a consistent sedation level and avoid repeated stimulation from bolus dosing.

Monitor sedation level (NPASS or unit-specific scale), respiratory effort, and blood pressure with each dose change. Oversedation causes respiratory depression — particularly relevant during attempted CPAP or NIV trials before intubation.

Hemodynamic monitoring

• Pre-ductal SpO2 (right hand): continuous, with alarm limits set at 91% lower and 97% upper
• Post-ductal SpO2 (foot): continuous monitoring during acute phase to detect gradient change
• Arterial line: umbilical arterial catheter (UAC) or peripheral arterial line for continuous BP monitoring and frequent ABG sampling. UAC tip position at T6–T9 (high position) allows sampling of pre-ductal blood.
• Central venous access: umbilical venous catheter (UVC) or PICC for vasopressors, parenteral nutrition, and medications that require central access
• Blood pressure: systemic hypotension worsens right-to-left shunting by reducing SVR below PVR. Target MAP within normal range for gestational age. Dopamine or dobutamine for hemodynamic support as ordered.
• Oxygenation Index: calculate every 4–6 hours and trend; document and report to provider

Positioning

Some infants with PPHN tolerate specific positions better than others due to differential effects on ventilation-perfusion matching. Right lateral decubitus position and prone positioning may improve oxygenation in selected patients — follow provider orders and document the infant’s response to each position change. Any repositioning should be done during a care cluster, not as an isolated event.

PICC and line care

PPHN infants require prolonged vascular access. PICC lines should be assessed at every shift for:

• Patency (aspirate blood return before each infusion)
• Site integrity (redness, swelling, skin breakdown)
• Securement (avoid tugging on the line during care; a dislodged central line in a PPHN infant is an emergency)
• Length from insertion site (measure external length each shift; migration changes infusion safety)

Parental support

PPHN is sudden, terrifying, and visually overwhelming for families. The infant is typically intubated, surrounded by ventilators and iNO delivery equipment, and covered in monitoring leads and lines. Parents need clear, jargon-free explanations and a realistic picture of prognosis.

Key nursing responsibilities:

• Explain what each piece of equipment does in plain language
• Normalize asking questions and visiting the bedside, while teaching visitors about minimal stimulation
• Involve the care team chaplain, social work, and child life specialists early
• Facilitate any safe parent contact (hand-holding, voice) during stable periods
• Document family education and understanding in the medical record

For families whose infants are being considered for ECMO, clear communication about what ECMO is, what it involves, and the criteria driving the decision is essential before consent. See NEC nursing for a parallel discussion of family communication in NICU emergencies at neonatal NEC nursing.

Long-term outcomes

Survival with modern PPHN management (iNO era) exceeds 85–90% for non-CDH PPHN. CDH-associated PPHN carries higher mortality (40–50% in severe cases). However, survival does not mean intact survival — survivors carry significant long-term risks that nurses should be able to discuss with families.

Sensorineural hearing loss

Sensorineural hearing loss (SNHL) is one of the most common long-term sequelae of PPHN. Two mechanisms operate independently and synergistically:

1. Hypoxia: The cochlea is exquisitely sensitive to oxygen deprivation. Prolonged or episodic hypoxemia during the acute illness causes ischemic damage to cochlear hair cells — particularly the outer hair cells of the basal turn, which respond to high frequencies.

2. Noise: NICU environments are loud (60–80 dB average, with transient peaks above 100 dB from equipment alarms and coupette doors). Prolonged exposure at these levels causes noise-induced hair cell damage. This is why NICU noise reduction is an active safety initiative in most units.

All PPHN survivors should have formal audiological assessment (auditory brainstem response or OAE testing) before discharge, with repeat testing at 3 and 6 months corrected age. Families should be counseled that hearing impairment can develop or worsen after discharge, even if the newborn screen is passed.

Neurodevelopmental impairment

Hypoxia, hemodynamic instability, and the metabolic consequences of critical illness during a period of rapid brain development create lasting neurological risk. PPHN survivors have elevated rates of:

• Cognitive delay (IQ below population mean on formal testing)
• Motor impairment, including mild cerebral palsy
• Speech and language delay
• Behavioral problems, including attention-deficit/hyperactivity disorder

Risk is highest in infants who experienced prolonged severe hypoxemia, required ECMO, had coexistent HIE, or had CDH. Families should be connected with early intervention programs before discharge and followed at a high-risk developmental follow-up clinic.

Bronchopulmonary dysplasia (BPD)

Infants who require prolonged mechanical ventilation and high FiO2 as part of PPHN management are at risk for BPD — chronic lung disease characterized by abnormal alveolar development and pulmonary vascular remodeling. BPD in this population is driven by both the original lung injury (e.g., MAS, RDS) and the ventilator-induced lung injury accumulated during treatment. BPD complicates weaning from respiratory support and may require chronic diuretic therapy, inhaled bronchodilators, and home oxygen after discharge.

NCLEX tips

1. The pre/post-ductal SpO2 test uses the RIGHT hand (not left) and either foot. The right hand is pre-ductal because the right subclavian originates proximal to the ductus arteriosus. The left hand may receive mixed blood in some patients depending on ductal flow — only the right hand is a reliable pre-ductal site.

2. A pre/post-ductal SpO2 gradient ≥10% is the positive threshold for PPHN screening. A difference of 5% is not significant. Memorize 10%.

3. PPHN improves with 100% FiO2 (hyperoxia test); fixed cyanotic CHD does not. This is the classic NCLEX differentiator. In PPHN, 100% O2 can overcome the functional shunt. In cyanotic CHD (e.g., transposition of the great arteries), the anatomical shunt is fixed and PaO2 remains low regardless of FiO2.

4. The OI formula: (FiO2 × MAP × 100) / PaO2. You will be given values and asked to calculate OI or identify the clinical meaning. OI > 25 = initiate iNO. OI > 40 (×2, ≥4 hours apart) = consider ECMO.

5. iNO standard dose is 20 ppm. Higher doses do not improve outcomes and increase methemoglobinemia risk. Expect an NCLEX question asking what to do if iNO is not working at 20 ppm — the answer is not to increase the dose but to reassess and consider the next step (sildenafil or ECMO criteria).

6. Never discontinue iNO abruptly. Abrupt withdrawal causes rebound PPHN. Wean by 5 ppm increments with continuous SpO2 monitoring. This is a near-certainty NCLEX topic for iNO management.

7. Minimal stimulation is a treatment in PPHN, not just a comfort measure. Stimulation causes reflex pulmonary vasoconstriction that can drop SpO2 rapidly. Nursing care is clustered to minimize stimulation events. Routine suctioning is contraindicated — suction only when indicated.

8. PPHN occurs predominantly in term and near-term infants (≥34 weeks), not premature infants. This is a key differentiator from RDS (premature) and BPD (premature, chronic). If the stem describes a 39-week infant with severe cyanosis and minimal response to oxygen, think PPHN first.

9. Sildenafil inhibits PDE5, prolonging cGMP and vasodilating pulmonary vessels. It is synergistic with iNO (iNO increases cGMP; sildenafil prevents its breakdown) and is frequently used as a bridge during iNO weaning to prevent rebound hypertension. Monitor blood pressure — systemic hypotension is the primary adverse effect.

10. All PPHN survivors need follow-up audiological assessment. Sensorineural hearing loss is a known long-term complication from both hypoxia and NICU noise exposure. A question asking what discharge teaching or follow-up appointments the nurse should arrange will almost always include audiology.

Key takeaways

PPHN is a failure of the normal postnatal fall in pulmonary vascular resistance, leading to continued right-to-left shunting through the foramen ovale and ductus arteriosus, profound hypoxemia, and right ventricular strain. It is a disease of term and near-term infants, most often triggered by MAS, sepsis, RDS, or CDH.

Bedside diagnosis rests on the pre/post-ductal SpO2 gradient (right hand vs foot, ≥10% difference) and is confirmed by echocardiography showing elevated pulmonary artery pressure and shunting. The Oxygenation Index drives escalation decisions: OI > 25 triggers iNO; OI > 40 twice triggers ECMO consideration.

Inhaled nitric oxide at 20 ppm is the first-line pulmonary vasodilator. It must be weaned slowly — abrupt discontinuation causes rebound PPHN. Sildenafil is synergistic with iNO via PDE5 inhibition and is used as an adjunct and bridge during weaning.

The nursing role in PPHN is defined by the minimal stimulation protocol, rigorous hemodynamic monitoring, pre/post-ductal SpO2 surveillance, early identification of deteriorating OI trends, and family support during a frightening and prolonged intensive care admission. Survivors need audiological and neurodevelopmental follow-up — the damage from hypoxia does not always declare itself before discharge.